SCHEMBL9935970

SCHEMBL9935970

CC(C)(C=O)CNC1CCCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADH1B P00325 2/20 0.40
ADH1C P00326 2/20 0.40
ADH1A P07327 2/20 0.40
ADH4 P08319 1/20 0.40
ADH7 P40394 1/20 0.37
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
DPP7 Q9UHL4 1/20 0.36
EPHX1 P07099 3/20 0.35
LMNA P02545 1/20 0.34
CXCR4 P61073 3/20 0.33
ANPEP P15144 2/20 0.33
ERAP2 Q6P179 2/20 0.33
KMT2A Q03164 2/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
PDK1 Q15118 1/20 0.33
PDK2 Q15119 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23137867 1.00 ADH1B (0.40) ADH1BADH1CADH1AADH4ADH7
SCHEMBL94568 0.77 ADH1B (0.38) ADH1BADH1CADH1AADH4ADH7
SCHEMBL11053891 0.76 KDM4E (0.43) KDM4EDPP7EPHX1ANPEPERAP2
SCHEMBL18177820 0.76 KDM4E (0.43) KDM4EDPP7EPHX1ANPEPERAP2
SCHEMBL342300 0.74 ADH1B (0.48) ADH1BADH1CADH1AADH4ADH7
SCHEMBL9285591 0.73 KDM4E (0.39) KDM4EDPP7EPHX1KMT2ACYP1A2
SCHEMBL15114086 0.72 KDM4E (0.40) KDM4EL3MBTL1DPP7EPHX1ANPEP
SCHEMBL11149818 0.72 KDM4E (0.40) KDM4EL3MBTL1DPP7EPHX1ANPEP
SCHEMBL17642227 0.72 KDM4E (0.40) KDM4EDPP7EPHX1KMT2ACYP1A2
SCHEMBL7123522 0.72 KDM4E (0.45) KDM4EL3MBTL1DPP7EPHX1ANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2651876-B1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECH AG (CH) 2017-08-09 EP claimed
CN-103261146-B Polyamines having secondary aliphatic amino groups SIKA TECHNOLOGY AG (CH) 2016-01-27 CN claimed
US-8877955-B2 Secondary aminosilanes SIKA TECHNOLOGY AG (CH) 2014-11-04 US claimed
US-20130281562-A1 SECONDARY AMINOSILANES SIKA TECHNOLOGY AG (CH) 2013-10-24 US claimed
EP-2651956-A1 SECONDARY AMINOSILANES Sika Technology AG (CH) 2013-10-23 EP claimed
US-20130261270-A1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2013-10-03 US claimed
EP-2468759-A1 Secondary Aminosilanes Sika Technology AG (CH) 2012-06-27 EP claimed
WO-2012080266-A1 SECONDARY AMINOSILANES SIKA TECHNOLOGY AG (CH) 2012-06-21 WO claimed
EP-2465843-A1 Polyamines with secondary aliphatic amines Sika Technology AG (CH) 2012-06-20 EP claimed
EP-3484898-B1 METHOD OF STABILIZING IMINO-FUNCTIONAL SILANE MOMENTIVE PERFORMANCE MAT INC (US) 2023-06-28 EP disclosed
EP-4053134-A1 METHOD OF STABILIZING IMINO-FUNCTIONAL SILANE Momentive Performance Materials Inc. (US) 2022-09-07 EP disclosed
CN-109563111-B Method for stabilizing imino-functional silanes 莫门蒂夫性能材料股份有限公司 2022-04-12 CN disclosed
US-11230563-B2 Method of stabilizing imino-functional silane MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2022-01-25 US disclosed
US-10457697-B2 Method of stabilizing imino-functional silane MOMENTIVE PERFORMANCE MATERIALS INC. (US) 2019-10-29 US disclosed
EP-2651876-A1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS Sika Technology AG (CH) 2013-10-23 EP disclosed
US-20130261270-A1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2013-10-03 US disclosed
EP-2468759-A1 Secondary Aminosilanes Sika Technology AG (CH) 2012-06-27 EP disclosed
WO-2012080266-A1 SECONDARY AMINOSILANES SIKA TECHNOLOGY AG (CH) 2012-06-21 WO disclosed
WO-2012080265-A1 POLYAMINES HAVING SECONDARY ALIPHATIC AMINO GROUPS SIKA TECHNOLOGY AG (CH) 2012-06-21 WO disclosed
EP-2465843-A1 Polyamines with secondary aliphatic amines Sika Technology AG (CH) 2012-06-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230563-B2 Method of stabilizing imino-functional silane INF2, RNF168, BOLA2; BOLA2B ADH1B 3143/4885ADH1C 1896/4885ADH1A 1807/4885
US-20130281562-A1 SECONDARY AMINOSILANES AS3MT, SRM, MSN ADH1B 4383/4885ADH1C 4472/4885ADH1A 3967/4885
US-10457697-B2 Method of stabilizing imino-functional silane INF2, RNF168, BOLA2; BOLA2B ADH1B 3143/4885ADH1C 1896/4885ADH1A 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.